FLC Capital Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$353K Buy
2,796
+100
+4% +$13.2K 0.06% 168
2026
Q1
$376K Sell
2,696
-3
-0.1% -$420 0.07% 153
2025
Q4
$331K Hold
2,699
0.06% 153
2025
Q3
$300K Buy
2,699
+2
+0.1% +$227 0.06% 162
2025
Q2
$299K Buy
2,697
+1
+0% +$106 0.06% 159
2025
Q1
$302K Hold
2,696
0.07% 144
2024
Q4
$249K Hold
2,696
0.06% 152
2024
Q3
$226K Buy
+2,696
New +$206K 0.05% 157
2024
Q2
Sell
-2,831
Closed -$207K 171
2024
Q1
$207K Hold
2,831
0.05% 157
2023
Q4
$229K Hold
2,831
0.06% 137
2023
Q3
$212K Hold
2,831
0.06% 141
2023
Q2
$218K Hold
2,831
0.06% 140
2023
Q1
$235K Sell
2,831
-520
-16% -$43.1K 0.07% 141
2022
Q4
$288K Buy
3,351
+95
+3% +$7.52K 0.09% 130
2022
Q3
$201K Sell
3,256
-2,370
-42% -$149K 0.07% 154
2022
Q2
$348K Hold
5,626
0.12% 115
2022
Q1
$334K Sell
5,626
-1,500
-21% -$95.9K 0.09% 126
2021
Q4
$517K Sell
7,126
-4,293
-38% -$296K 0.14% 114
2021
Q3
$798K Sell
11,419
-500
-4% -$35.1K 0.24% 91
2021
Q2
$821K Hold
11,919
0.24% 87
2021
Q1
$770K Buy
11,919
+950
+9% +$61.3K 0.24% 85
2020
Q4
$639K Buy
10,969
+3,750
+52% +$226K 0.21% 85
2020
Q3
$437K Buy
+7,219
New +$501K 0.16% 99

Other funds holding GILD

FLC Capital Advisors's GILD Position: Q2 2026 in Review

FLC Capital Advisors increased its Gilead Sciences (GILD) stake by 3.7% in Q2 2026, buying an estimated $13.2K and bringing the position to 2,796 shares worth $353K. The position accounts for 0.06% of the portfolio, ranked #168.

FLC Capital Advisors first reported a position in GILD in Q3 2020 and has held it in 23 quarters since. The position peaked at $821K in Q2 2021. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • FLC Capital Advisors held 2,796 shares of Gilead Sciences worth $353K as of Q2 2026.
  • FLC Capital Advisors bought 100 Gilead Sciences shares in Q2 2026, an estimated $13.2K.
  • Gilead Sciences made up 0.06% of FLC Capital Advisors's portfolio in Q2 2026, its #168 holding.
  • FLC Capital Advisors first reported a position in Gilead Sciences in Q3 2020 and has held it in 23 quarters since.
  • FLC Capital Advisors's Gilead Sciences position peaked at $821K in Q2 2021.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on FLC Capital Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.